195 related articles for article (PubMed ID: 34830747)
21. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.
Sermer D; Batlevi C; Palomba ML; Shah G; Lin RJ; Perales MA; Scordo M; Dahi P; Pennisi M; Afuye A; Silverberg ML; Ho C; Flynn J; Devlin S; Caron P; Hamilton A; Hamlin P; Horwitz S; Joffe E; Kumar A; Matasar M; Noy A; Owens C; Moskowitz A; Straus D; von Keudell G; Rodriguez-Rivera I; Falchi L; Zelenetz A; Yahalom J; Younes A; Sauter C
Blood Adv; 2020 Oct; 4(19):4669-4678. PubMed ID: 33002134
[TBL] [Abstract][Full Text] [Related]
22. Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma.
Ping N; Qu C; Li M; Kang L; Kong D; Chen X; Wu Q; Xia F; Yu L; Yao H; Yan L; Wu D; Jin Z
Ann Transl Med; 2022 Mar; 10(6):298. PubMed ID: 35433994
[TBL] [Abstract][Full Text] [Related]
23. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
24. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
25. Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report.
Huang C; Zhang HC; Ho JY; Liu RX; Wang L; Kuang N; Zheng MR; Liu LH; Li JQ
Oncol Lett; 2020 Oct; 20(4):21. PubMed ID: 32774494
[TBL] [Abstract][Full Text] [Related]
26. CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.
Chen L; Xu B; Long X; Gu J; Lou Y; Wang D; Cao Y; Wang N; Li C; Wang G; Wang Y; Zhu L; Wang J; An H; Xiao M; Xiao Y; Zhou J
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345625
[TBL] [Abstract][Full Text] [Related]
27. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
[TBL] [Abstract][Full Text] [Related]
28. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
29.
Dobashi A; Togashi Y; Tanaka N; Yokoyama M; Tsuyama N; Baba S; Mori S; Hatake K; Yamaguchi T; Noda T; Takeuchi K
Oncotarget; 2018 Apr; 9(28):19555-19568. PubMed ID: 29731965
[TBL] [Abstract][Full Text] [Related]
30. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.
You H; Xu-Monette ZY; Wei L; Nunns H; Nagy ML; Bhagat G; Fang X; Zhu F; Visco C; Tzankov A; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Van Krieken JH; Piris MA; Winter JN; Li Y; Au Q; Xu B; Albitar M; Young KH
Oncoimmunology; 2021; 10(1):1928365. PubMed ID: 34350060
[TBL] [Abstract][Full Text] [Related]
31. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
32. Salvage Radiation Treatment for Primary Refractory Diffuse Large B-cell Lymphoma After Chimeric Antigen Receptor (CAR) T-cell Therapy: A Case Report.
Wang K; Prabhu AV; Sasapu A; Lewis GD
Anticancer Res; 2021 Jul; 41(7):3635-3638. PubMed ID: 34230160
[TBL] [Abstract][Full Text] [Related]
33. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
[TBL] [Abstract][Full Text] [Related]
34. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
Epperla N; Maddocks KJ; Salhab M; Chavez JC; Reddy N; Karmali R; Umyarova E; Bachanova V; Costa C; Glenn M; Calzada O; Xavier AC; Zhou Z; Hossain NM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Barta SK; Chhabra S; Lansigan F; Mehta A; Jaglal MV; Evens AM; Flowers CR; Cohen JB; Fenske TS; Hamadani M; Costa LJ
Cancer; 2017 Nov; 123(22):4411-4418. PubMed ID: 28749548
[TBL] [Abstract][Full Text] [Related]
35. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
[TBL] [Abstract][Full Text] [Related]
36. Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study.
Cheng R; Scippa K; Locke FL; Snider JT; Jim H
Oncol Ther; 2022 Jun; 10(1):123-141. PubMed ID: 34778941
[TBL] [Abstract][Full Text] [Related]
37. Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy.
Seipel K; Abbühl M; Bacher U; Nilius H; Daskalakis M; Pabst T
Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37297020
[TBL] [Abstract][Full Text] [Related]
38. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
39. CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement.
Shumilov E; Boyadzhiev H; Mazzeo P; Akhoundova D; Daskalakis M; Novak U; Lenz G; Bacher U; Pabst T
Hemasphere; 2023 Dec; 7(12):e984. PubMed ID: 38044958
[TBL] [Abstract][Full Text] [Related]
40. Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients.
Nydegger A; Novak U; Kronig MN; Legros M; Zeerleder S; Banz Y; Bacher U; Pabst T
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]